High rate of rubella seronegativity in perinatally-infected HIV women of childbearing age: A case-control study

Vaccine. 2019 Sep 20;37(40):5930-5933. doi: 10.1016/j.vaccine.2019.08.034. Epub 2019 Aug 23.

Abstract

Rubella infection is a vaccine preventable disease. Maternal infection during pregnancy may lead to congenital infection and severe foetal malformations. Thanks to antiretroviral therapy, perinatally HIV-infected women have better prognosis and are now experiencing pregnancy. We evaluated the rate of rubella seronegativity in a cohort of HIV perinatally-infected women of childbearing age. A high rate of seronegativity was found in this group as compared to age-matched non-perinatally infected HIV-infected women (34.5% vs 6.90%, p < 0.01). MMR administration before rubella testing was identified in 75.8% of perinatally-infected women (22/29) with a mean of 2 doses (range: 1-3 doses). HIV perinatally-infected women of childbearing age should be screened repeatedly for rubella immunity.

Keywords: HIV; Rubella vaccine; Seroprevalence; Vaccine; Vertical transmission.

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Viral / immunology
  • Case-Control Studies
  • Cohort Studies
  • Female
  • HIV Infections / immunology*
  • HIV Infections / virology
  • Humans
  • Mass Screening / methods
  • Measles / immunology
  • Measles-Mumps-Rubella Vaccine / immunology
  • Pregnancy
  • Rubella / immunology*
  • Rubella Syndrome, Congenital / immunology*
  • Rubella Syndrome, Congenital / virology
  • Vaccination / methods
  • Young Adult

Substances

  • Antibodies, Viral
  • Measles-Mumps-Rubella Vaccine